SDKI Inc. published a new research report on "Pulmonary Arterial Hypertension (PAH) Market-Forecast 2022-2031" on January 25, 2022. The report provides a complete assessment of the market and its growth prospects, along with new business opportunities in the industry. It also includes market size and annual growth during the 2022-2031 forecast period.
The pulmonary arterial hypertension (PAH) market is estimated to reach US $ 11.60 billion by 2031, from a market value of US $ 7.15 billion in 2022, growing at a CAGR of 5.6% during the 2022-2031 forecast period. Is expected.
https://www.sdki.jp/press-details/pulmonary-arterial-hypertension-pah-market/630
Pulmonary arterial hypertension is a debilitating condition, with increased pulmonary vascular resistance and pulmonary arteries. Characterized by pressure. This condition can lead to damage to the right ventricle or death of the patient. PAH may be associated with conditions such as hereditary, idiopathic, or congenital heart disease, connective tissue disease, hypertension, and HIV infection. PAHs are classified as underestimated because the prevalence of this disorder is very low, with an estimated prevalence of approximately 15-50 cases per million people. However, the prevalence of this disorder has increased over the past few years due to risk factors such as smoking, tobacco consumption, sedentary lifestyles, and other idiopathic conditions.
The growth of the pulmonary arterial hypertension market is driven primarily by the government's favorable initiative for the development of orphan drugs. The government benefits in terms of enhanced patent protection, tax incentives, and more. The Orphan Drug Act of 2002 and the Orphan Drug Act of 1983 (ODA) are two important laws that promote the distribution and ethical use of orphan drugs. ODA promotes tax credits of up to 50.0% of overall research funding, protocol support, US FDA fee exemptions, and clinical tax incentives. This factor encourages key players to invest in this industry and significantly drives the growth of the pulmonary arterial hypertension (PAH) market.
Pulmonary arterial hypertension (PAH) market segment
The pulmonary arterial hypertension (PAH) market is divided by drug class (prostacyclin and analogs, SGC stimulants, ERA and phosphodiesterase-5), and by region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.
Regional Overview of the Pulmonary Arterial Hypertension (PAH) Market
In addition, the report covers all regions of the world, divided into North America, Europe, Asia Pacific, Latin America, the Middle East / Africa and more. The North American region has the largest share of the global pulmonary arterial hypertension (PAH) market. This is due to the medical infrastructure developed in the United States that facilitates access to advanced therapies. In addition, heightened awareness, high diagnostic rates, and government-backed initiatives are driving the growth of the region's pulmonary arterial hypertension (PAH) market during the forecast period. A well-planned redemption structure and high awareness have resulted in excellent diagnostic rates.
For further analysis, each region is further subdivided into countries:
· Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Singapore, and other Asia Pacific)
· North America (US and Canada)
· Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa)
· Latin America (Brazil, Mexico, Argentina, and others) Latin America)
· Leading player in the pulmonary arterial hypertension (PAH) market in Europe (UK, Germany, France, Italy, Spain, Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) Pulmonary arterial
lung Key players in the hypertension (PAH) market include Pfizer, Inc., GlaxoSmithKline, Novartis, Bayer and Merck. The study includes a detailed competitive analysis of these leading companies in the pulmonary arterial hypertension (PAH) market, corporate profiles, recent developments, and key market strategies.
Sample URL of the report
https://www.sdki.jp/sample-request-53279
SDKI Inc. Company Profile
SDKI Inc.'s goal is market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.
https://www.sdki.jp/press-details/pulmonary-arterial-hypertension-pah-market/630
Pulmonary arterial hypertension is a debilitating condition, with increased pulmonary vascular resistance and pulmonary arteries. Characterized by pressure. This condition can lead to damage to the right ventricle or death of the patient. PAH may be associated with conditions such as hereditary, idiopathic, or congenital heart disease, connective tissue disease, hypertension, and HIV infection. PAHs are classified as underestimated because the prevalence of this disorder is very low, with an estimated prevalence of approximately 15-50 cases per million people. However, the prevalence of this disorder has increased over the past few years due to risk factors such as smoking, tobacco consumption, sedentary lifestyles, and other idiopathic conditions.
The growth of the pulmonary arterial hypertension market is driven primarily by the government's favorable initiative for the development of orphan drugs. The government benefits in terms of enhanced patent protection, tax incentives, and more. The Orphan Drug Act of 2002 and the Orphan Drug Act of 1983 (ODA) are two important laws that promote the distribution and ethical use of orphan drugs. ODA promotes tax credits of up to 50.0% of overall research funding, protocol support, US FDA fee exemptions, and clinical tax incentives. This factor encourages key players to invest in this industry and significantly drives the growth of the pulmonary arterial hypertension (PAH) market.
Pulmonary arterial hypertension (PAH) market segment
The pulmonary arterial hypertension (PAH) market is divided by drug class (prostacyclin and analogs, SGC stimulants, ERA and phosphodiesterase-5), and by region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.
Regional Overview of the Pulmonary Arterial Hypertension (PAH) Market
In addition, the report covers all regions of the world, divided into North America, Europe, Asia Pacific, Latin America, the Middle East / Africa and more. The North American region has the largest share of the global pulmonary arterial hypertension (PAH) market. This is due to the medical infrastructure developed in the United States that facilitates access to advanced therapies. In addition, heightened awareness, high diagnostic rates, and government-backed initiatives are driving the growth of the region's pulmonary arterial hypertension (PAH) market during the forecast period. A well-planned redemption structure and high awareness have resulted in excellent diagnostic rates.
For further analysis, each region is further subdivided into countries:
· Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Singapore, and other Asia Pacific)
· North America (US and Canada)
· Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa)
· Latin America (Brazil, Mexico, Argentina, and others) Latin America)
· Leading player in the pulmonary arterial hypertension (PAH) market in Europe (UK, Germany, France, Italy, Spain, Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) Pulmonary arterial
lung Key players in the hypertension (PAH) market include Pfizer, Inc., GlaxoSmithKline, Novartis, Bayer and Merck. The study includes a detailed competitive analysis of these leading companies in the pulmonary arterial hypertension (PAH) market, corporate profiles, recent developments, and key market strategies.
Sample URL of the report
https://www.sdki.jp/sample-request-53279
SDKI Inc. Company Profile
SDKI Inc.'s goal is market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.
